Day: January 13, 2021

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program

The CF Foundation’s partial funding of the U.S. trial has been extended to partial funding of the global clinical trial...

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

Roflumilast cream potential “Best in Class” topical PDE4 inhibitorAtopic dermatitis affects approximately 19 million patients in the U.S.The Company anticipates...

error: Content is protected !!